Neutrophil calprotectin identifies severe pulmonary disease in COVID-19

Hui Shi¹,²*, Yu Zuo¹*, Srilakshmi Yalavarthi¹, Kelsey Gockman¹, Melanie Zuo³, Jacqueline A. Madison¹, Christopher N. Blair⁴, Robert J. Woods⁴, Christian Lood⁵, Jason S. Knight⁶, and Yogendra Kanthi⁶,⁷‡

* These authors contributed equally and share first authorship.
‡ Jason S. Knight and Yogendra Kanthi are co-corresponding authors.

Affiliations
¹ Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
² Division of Rheumatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
³ Division of Geriatric and Palliative Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
⁴ Division of Infectious Disease, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
⁵ Division of Rheumatology, University of Washington, Department of Medicine, Seattle, Washington, USA
⁶ Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
⁷ Division of Cardiology, Ann Arbor Veterans Administration Healthcare System, Ann Arbor, Michigan, USA

Correspondence: Jason S. Knight, MD, PhD  Yogendra Kanthi, MD
jsknight@umich.edu  ykanthi@umich.edu

Competing interests: The authors have no financial conflicts to report.
ABSTRACT
Severe cases of coronavirus disease 2019 (COVID-19) are regularly complicated by respiratory failure. While it has been suggested that elevated levels of blood neutrophils associate with worsening oxygenation in COVID-19, it is unknown whether neutrophils are drivers of the thrombo-inflammatory storm or simple bystanders. We now report that patients with COVID-19 (n=96) have markedly elevated levels of the neutrophil activation marker S100A8/A9 (calprotectin) in their blood. Calprotectin tracked with other acute phase reactants including C-reactive protein, D-dimer, ferritin, and absolute neutrophil count, but was superior in identifying patients requiring mechanical ventilation. In longitudinal samples, calprotectin rose as oxygenation worsened. When tested on day 1 or 2 of hospitalization (n=52 patients), calprotectin levels were significantly higher in patients who progressed to severe COVID-19 requiring mechanical ventilation (7805 ± 7585, n=23) as compared to those who remained free of intubation (3123 ± 2990, p=0.0059). In summary, serum calprotectin levels track closely with current and future COVID-19 severity, strongly implicating neutrophils as active perpetuators of inflammation and respiratory compromise in COVID-19.
INTRODUCTION
Since December 2019, the outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread to hundreds of countries and has been declared a global pandemic. Severe COVID-19 results in death due to progressive hypoxemia, acute respiratory distress syndrome (ARDS), and multi-organ failure. The role of the host response in this progression remains to be fully defined.

S100A8 (MRP8) and S100A9 (MRP14) are calcium-binding proteins that belong to the S100 family. They exist mainly together as a biologically-functional heterodimer known as S100A8/A9 or calprotectin. Calprotectin is found in abundance in neutrophils, where it can account for almost two-thirds of soluble protein in the cytosol. Calprotectin may also be detected at low levels in monocytes, reactive macrophages, platelets, and squamous epithelial cells. Upon neutrophil activation or death, calprotectin is released extracellularly where it has microbicidal functions (via heavy-metal chelation) and also serves as a pro-inflammatory ligand for Toll-like receptor 4. Given its small size, easy diffusion between tissue and blood, and resistance to enzymatic degradation, calprotectin is a sensitive and dynamic marker of neutrophil activation anywhere in the body. High levels of calprotectin have been found in many types of infectious and inflammatory diseases—including sepsis, myocardial infarction, inflammatory bowel disease, lupus, and adult-onset Still's disease—where it tracks closely with disease severity.

While neutrophils are only beginning to be investigated in COVID-19, other pandemic viruses such as influenza H1N1 and MERS-CoV elicit neutrophilic infiltration at sites of infection. Indeed, the acute and exudative phase of ARDS is defined by an exuberant immune response productive of pro-inflammatory cytokines and chemokines, as well as neutrophil-mediated disruption of the alveolar epithelial-capillary barrier. Neutrophil-depleted mice demonstrate milder lung pathology in response to influenza infection, with lower levels of thrombomodulin, matrix metalloproteinases, and myeloperoxidase in bronchoalveolar lavage fluid. Moreover, high levels of neutrophils portend a worse prognosis in patients with influenza A infection.

Work to date exploring COVID-19 pathophysiology has focused especially on macrophages and their products such as interleukin-6 (IL-6) and IL-1β. While it has been suggested that elevated levels of blood neutrophils associate with worsening oxygenation in COVID-19, it is unknown whether neutrophils are drivers of the thrombo-inflammatory storm or simple bystanders. In particular, there is a paucity of information about neutrophil catalysts, checkpoints, and effector
mechanisms—all of which could add actionable context to our understanding of the COVID-19 inflammatory storm. Here, to better understand the potential role of activated neutrophils in COVID-19, we measured serum calprotectin in hospitalized patients and determined its relationship to severity of illness and respiratory status.

RESULTS

Detection of calprotectin in sera of COVID-19 patients. Serum samples were obtained from 96 patients hospitalized with COVID-19 at a large academic hospital (Table 1). As compared with serum samples from 47 healthy controls, the COVID-19 samples showed markedly higher levels of calprotectin (Figure 1A). For a subset of the patients, longitudinal serum samples were available. Eight of those patients showed a clinically meaningful change in oxygenation status during the period of collection (five worsening, three improving). Calprotectin levels trended upward as oxygenation worsened and downward as oxygenation improved (Figure 1B). In summary, calprotectin is markedly elevated in the sera of patients with COVID-19 and appears to rise as clinical status deteriorates.

Association between calprotectin and clinical lab studies. We next asked how calprotectin compared to commonly available clinical tests. Specifically, we assessed potential correlations with C-reactive protein, D-dimer, ferritin, lactate dehydrogenase, absolute neutrophil count, neutrophil-to-lymphocyte ratio, hemoglobin level, and platelet count. Calprotectin demonstrated a positive correlation with C-reactive protein, D-dimer, ferritin, lactate dehydrogenase, absolute neutrophil count, and neutrophil-to-lymphocyte ratio (Figure 2A-F). There was a negative correlation with hemoglobin level (Figure 2F) and a positive correlation with platelet count (Figure 2G). The strongest correlations were with C-reactive protein (r=0.51, p<0.0001) and absolute neutrophil count (r=0.50, p<0.0001).

Calprotectin associates with severe disease including mechanical ventilation. We next determined each patient’s clinical respiratory status at the time calprotectin was measured. As compared with patients breathing room air, patients requiring mechanical ventilation had significantly higher levels of calprotectin (Figure 3A). Differences were also appreciated between patients requiring nasal-cannula oxygen and mechanical ventilation (Figure 3A). Absolute neutrophil count also differentiated between these same groups, albeit with lower p values (Figure 3B). In contrast, neither neutrophil-to-lymphocyte ratio nor C-reactive protein discriminated between patients requiring nasal-cannula oxygen and mechanical ventilation.
Beyond clinical respiratory status, oxygenation efficiency can also be measured by comparing pulse oximetry (SpO₂) to the fraction of inspired oxygen (FiO₂). We tested the correlation between calprotectin and SpO₂/FiO₂ ratio, and found a strong negative association (Figure 3E). Of the 96 patients evaluated here, 52 had sera available from the first two days of their hospitalization. Calprotectin levels were significantly higher in those individuals who required mechanical ventilation at any point during their hospitalization (n=23), as compared with those who did not (p=0.0059, Figure 3F). Taken together, these data suggest a compelling relationship between neutrophil activation, as defined by serum calprotectin levels, and severe respiratory disease in COVID-19.

DISCUSSION

Here, we report markedly elevated levels of serum calprotectin indicative of neutrophil activation in the majority of patients hospitalized with COVID-19. Furthermore, we found that high levels of serum calprotectin on day 1 or 2 of hospitalization tracked with a requirement for mechanical ventilation at any point during the admission, a finding that should be urgently assessed in larger prospective cohorts. These data provide strong evidence in support of activated neutrophils as indispensable players in moderate-to-severe cases of COVID-19. Triggers of neutrophil activation are potentially numerous and might include virus-damaged epithelial cells\(^{14,18}\); activated endothelial cells\(^{19}\); activated platelets\(^{20,21}\); cytokines such as IL-1\(\beta\)\(^{22,23}\), granulocyte colony stimulating factor\(^{24,25}\), and IL-8\(^{26,27}\); and potentially even direct interaction with the virus itself, in particular if opsonized with IgG antibodies.

In addition to being an inflammatory marker, calprotectin may also have a direct role in the self-amplifying thrombo-inflammatory storm that afflicts many COVID-19 patients. Calprotectin engages innate immune sensors such as TLR4\(^{28}\) to activate the transcription factor NFkB\(^{29}\) and ultimately trigger the production of pro-inflammatory cytokines\(^{30}\). Depending on the system, calprotectin has been detected both upstream\(^{31}\) and downstream\(^{32}\) of IL-6, which has emerged as a possible therapeutic target in COVID-19. Calprotectin is also a potent stimulator of neutrophils themselves, promoting degranulation and phagocytosis\(^{33,34}\), as well as other more recently described effector functions such as neutrophil extracellular trap (NET) release\(^{35}\). Intriguingly, crosstalk between neutrophils, platelets, and calprotectin appears to play a role in both arterial and venous thrombosis\(^{35,36}\), which are being increasingly identified as complications of COVID-19\(^{37,38}\).
Not considered in this study is the specific form of neutrophil activation and cell death that floods COVID-19 patients with excess calprotectin. One consideration is NET release\textsuperscript{39,40}. NETs are extracellular webs of DNA, histones, and microbicidal proteins that appear to perpetuate many types of lung disease including smoking-related disease\textsuperscript{41}, cystic fibrosis\textsuperscript{42}, and ARDS\textsuperscript{14,43,44}. NETs leverage calprotectin as an antimicrobial strategy against Candida\textsuperscript{45} and Aspergillus\textsuperscript{46}, but, when left unchecked, NETs are also an important source of macrophage activation\textsuperscript{47,48} and microvascular occlusion\textsuperscript{49,50}. This is another topic that in our opinion requires further and urgent investigation.

Dipyridamole is an FDA-approved antiplatelet drug with a favorable side-effect profile that our group recently discovered to inhibit neutrophil activation via agonism of adenosine A\textsubscript{2A} receptors\textsuperscript{51}. In a small clinical trial performed in China, dipyridamole-treated patients demonstrated improvements in platelet counts and D-dimer levels\textsuperscript{52}, along with possible stabilization of clinical status. Given the urgent need for effective treatments of COVID-19, a randomized study to characterize the impact of dipyridamole on COVID-19-related neutrophil activation, thrombo-inflammatory storm, and clinical outcomes seems warranted. Other approaches to combatting neutrophil effector functions include dismantling already-formed NETs (deoxyribonucleases) and strategies that might prevent neutrophil activation and NET release such as inhibitors of neutrophil elastase and peptidylarginine deiminase \textsuperscript{453,54}. As we await definitive antiviral and immunologic solutions to the current pandemic, we posit that anti-neutrophil therapies\textsuperscript{53,54} may be part of a personalized strategy for some individuals affected by COVID-19 who are at risk for progression to respiratory failure. In this context, calprotectin is well-positioned to be an early indicator of patients with COVID-19 likely to progress to respiratory failure and who therefore require immunomodulatory treatment.

**METHODS**

**Human samples.** Serum samples from 96 hospitalized COVID-19 patients were used in this study. Blood was collected into serum separator tubes by a trained hospital phlebotomist. After completion of biochemical testing ordered by the clinician, the remaining serum was stored at 4°C for up to 48 hours before it was released to the research laboratory. Serum samples were immediately divided into small aliquots and stored at -80°C until the time of testing. All 96 patients had a confirmed COVID-19 diagnosis based on FDA-approved RNA testing. This study complied with all relevant ethical regulations, and was approved by the University of Michigan.
Institutional Review Board (HUM00179409), which waived the requirement for informed consent given the discarded nature of the samples. Healthy volunteers were recruited through a posted flyer; exclusion criteria for these controls included history of a systemic autoimmune disease, active infection, and pregnancy. For preparation of control serum, blood was collected into serum separator tubes by a trained hospital phlebotomist. These serum samples were divided into small aliquots and stored at -80°C until the time of testing.

Quantification of S100A8/A9 (calprotectin). Calprotectin levels were measured with the Human S100A8/S100A9 Heterodimer DuoSet ELISA (DY8226-05, R&D Systems) according to the manufacturer’s instructions.

Statistical analysis. When two groups were present, normally-distributed data were analyzed by two-sided t test and skewed data were analyzed by Mann-Whitney test. For three or more groups, analysis was by one-way ANOVA or Kruskal-Wallis test with correction for multiple comparisons. Correlations were tested by Pearson’s correlation coefficient. Data analysis was with GraphPad Prism software version 8. Statistical significance was defined as p<0.05.

ACKNOWLEDGEMENTS
The work was supported by a COVID-19 Cardiovascular Impact Research Ignitor Grant from the Michigan Medicine Frankel Cardiovascular Center as well as by the A. Alfred Taubman Medical Research Institute. YZ was supported by career development grants from the Rheumatology Research Foundation and APS ACTION. JAM was partially supported by the VA Healthcare System. JSK was supported by grants from the NIH (R01HL115138), Lupus Research Alliance, and Burroughs Wellcome Fund. YK was supported by the NIH (K08HL131993, R01HL150392), Falk Medical Research Trust Catalyst Award, and the JOBST-American Venous Forum Award.

AUTHORSHIP
HS, YZ, SY, KG, MZ, JM, and CB conducted experiments and analyzed data. HS, YZ, RJW, CL, JSK, and YK conceived the study and analyzed data. All authors participated in writing the manuscript and gave approval before submission.
REFERENCES


### Table 1: COVID-19 patient characteristics

#### Demographics

<table>
<thead>
<tr>
<th>Number</th>
<th>Age (years)*</th>
<th>Hospital day** ‡</th>
<th>Female</th>
<th>White/Caucasian</th>
<th>Black/African-American</th>
</tr>
</thead>
<tbody>
<tr>
<td>96</td>
<td>63 ± 19</td>
<td>4.4 ± 4.6</td>
<td>39 (41%)</td>
<td>43 (45%)</td>
<td>43 (45%)</td>
</tr>
</tbody>
</table>

#### Comorbidities

<table>
<thead>
<tr>
<th>Condition</th>
<th>Number</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes</td>
<td>40</td>
<td>42%</td>
</tr>
<tr>
<td>Ischemic heart disease</td>
<td>27</td>
<td>28%</td>
</tr>
<tr>
<td>Renal disease</td>
<td>30</td>
<td>31%</td>
</tr>
<tr>
<td>Lung disease</td>
<td>26</td>
<td>27%</td>
</tr>
<tr>
<td>Autoimmune</td>
<td>5</td>
<td>5%</td>
</tr>
<tr>
<td>Cancer</td>
<td>14</td>
<td>15%</td>
</tr>
<tr>
<td>History of stroke</td>
<td>9</td>
<td>9%</td>
</tr>
<tr>
<td>Obesity</td>
<td>45</td>
<td>47%</td>
</tr>
<tr>
<td>Hypertension</td>
<td>66</td>
<td>69%</td>
</tr>
<tr>
<td>Immune deficiency</td>
<td>5</td>
<td>5%</td>
</tr>
<tr>
<td>History of smoking</td>
<td>29</td>
<td>30%</td>
</tr>
</tbody>
</table>

#### Medications‡

<table>
<thead>
<tr>
<th>Medication</th>
<th>Number</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydroxychloroquine</td>
<td>27</td>
<td>28%</td>
</tr>
<tr>
<td>Anti-IL6 receptor</td>
<td>4</td>
<td>4%</td>
</tr>
<tr>
<td>ACE inhibitor</td>
<td>2</td>
<td>2%</td>
</tr>
<tr>
<td>Angiotensin receptor blocker</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>Antibiotic</td>
<td>39</td>
<td>41%</td>
</tr>
<tr>
<td>Antiviral</td>
<td>4</td>
<td>4%</td>
</tr>
</tbody>
</table>

#### Respiratory status‡

<table>
<thead>
<tr>
<th>Respiratory Status</th>
<th>Number</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mechanical ventilation</td>
<td>35</td>
<td>36%</td>
</tr>
<tr>
<td>High-flow oxygen</td>
<td>5</td>
<td>5%</td>
</tr>
<tr>
<td>Nasal-cannula oxygen</td>
<td>35</td>
<td>36%</td>
</tr>
<tr>
<td>Room air</td>
<td>21</td>
<td>22%</td>
</tr>
</tbody>
</table>

* Mean ± standard deviation  
** Median = 2.5  
‡ At time of first sample available for testing
Figure 1: Detection of calprotectin in sera of COVID-19 patients. **A**, Sera from COVID-19 patients (n=96) and healthy controls (n=47) were assessed for calprotectin (note log scale). COVID-19 samples were compared to controls by Mann-Whitney test; ****p<0.0001. **B**, Eight of the COVID-19 patients had longitudinal samples available during a time in which they had a significant change in oxygenation status.
Figure 2: Association between calprotectin and clinical studies. Calprotectin levels (n=96) were compared to clinical laboratory results (when available on the same day as the research...
sample). Correlation coefficients were calculated for C-reactive protein (A), D-dimer (B), ferritin (C), lactate dehydrogenase (D), absolute neutrophil count (E), neutrophil-to-lymphocyte ratio (F), hemoglobin (G), and platelets (H).
Figure 3: Levels of calprotectin track closely with oxygenation status. Patients (n=96) were grouped by clinical status (room air vs. nasal cannula vs. mechanical ventilation) and analyzed for calprotectin (A), absolute neutrophil count (B), neutrophil-to-lymphocyte ratio (C), and C-reactive protein (D). Groups were compared by Kruskal-Wallis test corrected by Dunn's test for multiple comparisons; *p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001. E, Calprotectin was compared to SpO₂/FiO₂ ratio for each patient. Correlation was determined by Pearson’s test. F, For 52 patients, a calprotectin level was available from hospital day 1 or 2. Here, patients are divided by whether they at any point required mechanical ventilation (vent ever, n=23) during their hospitalization. Groups were compared by Mann-Whitney test; **p<0.01.